• Improvements to our Immuno-Oncology panel

    In response to customer feedback and as part of Olink’s commitment to improve and develop our offering, a number of changes have been made to our Immuno-Oncology panel. Significant improvements in detectabilty have been made for two key existing assays, and four new assays that are highly relevant for immunotherapy applications have been incorporated, replacing four assays from the previous version of the panel. For full details please visit the panel update page.